The HemOnc Pulse

Dr. Hilal, of the Mayo Clinic, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss measurable residual disease (MRD) and the debates surrounding its use for response assessment in patients with chronic lymphocytic leukemia (CLL).

Recorded at the first “HemOnc Pulse” Live meeting, this podcast episode features a panel discussion on unanswered questions in Hodgkin lymphoma with Andrew Evens, DO, MBA, MSc, Director of the Lymphoma Program and Associate Director of Rutgers Cancer Institute; Grzegorz Nowakowski, MD, a Professor of Oncology and Medicine in Division of Hematology at the Mayo Clinic; and Jane Winter, MD, a Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine.

Recorded at the first “HemOnc Pulse” Live meeting, this podcast episode features a panel discussion on unanswered questions in myelodysplastic syndromes (MDS) with Rami Komrokji, MD, Vice-Chair of the Malignant Hematology Department at Moffitt Cancer Center; Sanam Loghavi, MD, an Associate Professor of Pathology at the University of Texas MD Anderson Cancer Center; Jamile Shammo, MD, FACP, FASCP, a Professor at the Northwestern University Feinberg School of Medicine; Sangeetha Venugopal, MD, MS, an Assistant Professor of Medicine at the University of Miami Sylvester Comprehensive Cancer Center; and Amer Zeidan, MBBS, MHS, an Associate Professor of Medicine at Yale University.

This podcast episode features a panel discussion on challenges and opportunities for hematology oncology fellows with Megan Melody, MD, a third-year fellow at Northwestern University; Alexandra Rojek, MD, a second-year fellow at the University of Chicago Medicine Comprehensive Care Center; Seda Tolu, MD, a third-year fellow at the Columbia University Herbert Irving Comprehensive Cancer Center; Zaker Schwabkey, MD, a third-year fellow at Moffit Cancer Center; Himachandana Atluri, MD, a third-year fellow at the University of Texas MD Anderson Cancer Center; and Hannah Goulart, MD, a first-year fellow at MD Anderson Cancer Center.

“The HemOnc Pulse” goes on the road to Chicago May 3-4 with host Chadi Nabhan, MD, MBA, FACP, for the first live meeting. This podcast episode features a panel discussion on unanswered questions in chimeric antigen receptor (CAR) T-cell therapy with Caron Jacobson, MD, MMSc, Medical Director of the Immune Effector Cell Therapy Program at Dana-Farber Cancer Institute; Michael Bishop, MD, FACP, FASCO, Director of the Hematopoietic Stem Cell Transplantation Program at the University of Chicago; Joseph Mikhael, MD, MEd, FRCPC, FACP, a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Research Institute, an affiliate of the City of Hope Cancer Center; and Alan Skarbnik, MD, Director of the Lymphoma and Chronic Lymphocytic Leukemia Program and Director of Experimental Therapeutics, Malignant Hematology at Novant Health.

"The HemOnc Pulse" goes on the road to Chicago with host Chadi Nabhan, MD, MBA, FACP. This podcast episode features a panel discussion on unanswered questions in acute myeloid leukemia (AML) with Naval Daver, MD, an Associate Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center; Sanam Loghavi, MD, of the MD Anderson Cancer Center; Rami Komrokji, MD, the Vice-Chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida; and Mikkael Sekeres, MD, MS, a Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center at University of Miami Health.

On this episode of "The HemOnc Pulse," Alan Skarbnik, MD, of Novant Health, and Manni Mohyuddin, MBBS, of the University of Utah, discuss the concept of measurable residual disease (MRD) in hematologic malignancies and highlight the polarized views surrounding MRD. They also weigh the implications of MRD negativity, how to harmonize the MRD threshold, and how trials are putting MRD technology to the test.

On this episode of “The HemOnc Pulse,” Dr. Shammo, a Professor of Medicine in Hematology and Oncology at Northwestern Medicine, discusses how to approach treatment for myelodysplastic syndromes (MDS). Dr. Shammo speaks on everything from low- to high-risk treatment of patients with MDS, including why hypomethylating agents are the cornerstone for treating high-risk patients with MDS.

Dr. Patel, of the Swedish Cancer Institute in Seattle, Washington, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss novel frontline therapies in the lymphoma space, including the bispecific antibody glofitamab. They also discuss bispecifics versus chimeric antigen receptor (CAR) T-cell therapy, fixed duration therapy and step-up dosing, and how to sequence therapy.

In this episode of "The HemOnc Pulse," Dr. Goodman, an Associate Professor of Medicine at the University of California San Diego, joins Chadi Nabhan, MD, MBA, FACP, to discuss Castleman Disease. Dr. Goodman explains why the rare disease is often mismanaged, how each subtype is diagnosed and treated, and how it's comparable to hematologic cancers like lymphoma or myeloma.

Elias Jabbour, MD, an Executive Editor of Blood Cancers Today and a Professor of Leukemia at the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss the function of measurable residual disease in treating acute lymphocytic leukemia (ALL) and other progress that has been made in treating patients with Philadelphia chromosome-positive and Philadelphia chromosome-negative ALL. Dr. Jabbour also provides a brief historical perspective on tyrosine kinase inhibitors (TKIs), explaining how the therapies have improved survival outcomes in Ph+ ALL with or without transplantation.

Saurabh Dahiya, MD, FACP, of Stanford Medicine, and Jay Spiegel, MD, of the University of Miami, join The HemOnc Pulse for the second half of a two-part series on reports regarding secondary T-cell malignancies in patients after being treated with a chimeric antigen receptor (CAR) T-cell therapy and updates from the US Food and Drug Administration (FDA) on the issue. Drs. Dahiya and Spiegel return to the show shortly following the announcement that the FDA sent requests to drug manufacturers on January 9 to update prescription labels with "Black Box" warnings on the six CAR-T therapies used to treat blood cancers. Part one of the series covers the FDA's initial report in November 2023 and why it set off a "firestorm" in the hematology-oncology community.

In this season's fourth episode of "The HemOnc Pulse," Catherine Coombs, MD, an Associate Professor in the Division of Hematology/Oncology at the University of California, Irvine, School of Medicine, highlights recent studies in clonal hematopoiesis of indeterminate potential (CHIP) presented at the 65th American Society of Hematology Meeting & Exposition. Dr. Coombs discusses research on reversing the adverse effects of CHIP, particularly its association with atherosclerotic cardiovascular disease, using interventions such as selective nuclear export inhibitors. She also illustrates another study that looks at the prevalence of CHIP in patients undergoing autologous hematopoietic stem cell transplant in lymphoma, which showed an increased risk of cardiovascular disease and lower survival rates.

An all-new episode of The HemOnc Pulse with Saurabh Dahiya, MD, FACP, of Stanford Medicine, and Jay Spiegel, MD, of the University of Miami, features a discussion on the link between chimeric antigen receptor (CAR)-T cell therapies and secondary T-cell malignancies. The episode follows on the heels of the US Food and Drug Administration's request to drug manufacturers of the six CAR-T therapies to make safety-related labeling changes.

This episode features a conversation between Dr. Shastri, an Assistant Professor of Medicine at the Montefiore Einstein Comprehensive Cancer Center in the Bronx, New York, and The HemOnc Pulse host, Chadi Nabhan; MD; MBA; FACP; on the latest news in myelodysplastic syndromes (MDS), including the final readout from the COMMANDS trial and the clinical implications of TP53-mutated MDS.

The first episode of The HemOnc Pulse of the new year features an in-depth discussion by the leading researchers of the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) consortium. Principal investigators Susan Parsons, MD, MRP; and Andrew Evans, DO, MBA, MSc; are joined by Matthew Maurer, DMSc; to share the story behind harmonizing the world's Hodgkin lymphoma data, and what the effort means for both clinicians and patients.

Saad Usmani, MD, MBA, FACP, Chief of the Myeloma Service at the Memorial Sloan Kettering Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, on The HemOnc Pulse to chat about the latest research in multiple myeloma from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing in the hematologic oncology space. He also reflects on the Perseus and IsKia trials, which were presented at ASH 2023.

Sangeetha Venugopal, MD, of the University of Miami Sylvester Comprehensive Cancer Center, offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes (MDS), the COMMANDS trial, and if she believes MDS is a distinct disease. She also highlights the latest research in MDS at the 65th American Society of Hematology Annual Meeting and Exposition.

In this episode of The HemOnc Pulse, Jerald Radich, MD, of the Fred Hutchinson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss various abstracts on acute myeloid leukemia (AML) presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition. The conversation centered around menin inhibitors for the treatment of AML, the effect of measurable residual disease-positivity on transplantation outcomes, and whether age plays a role in transplantation.

In this episode of The HemOnc Pulse, Grzegorz Nowakowski MD, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic, recounts his experience serving on the FDA Oncologic Drugs Advisory Committee that reviewed and evaluated data from the POLARIX study and polatuzumab vedotin-piiq (Polivy)for patients with previously untreated LBCL.